AI-Powered Early Skin Cancer Detection & Diagnostic Platform

Summary

Folio3 AI partnered with Speclipse to transform skin cancer diagnostics by integrating cutting-edge Laser-Induced Plasma Spectroscopy (LIPS) with Deep Learning algorithms. The resulting "SkinMap" platform enables real-time, non-invasive skin screening, providing users and clinicians with instant risk assessments, intelligent body mapping, and a seamless bridge to specialist care.

Customer

Speclipse is a medical technology innovator founded by Stanford University alumni. They specialize in laser spectroscopic and AI-based diagnostic solutions, aiming to eliminate unnecessary biopsies and improve survival rates through early detection.

Challenges

• Subjective Diagnosis: Traditional skin monitoring relies on visual observation, which is prone to human error and late-stage detection.
• Invasive Procedures: Confirming malignancy typically requires painful and costly biopsies, often for benign lesions.
• Accessibility Gaps: A lack of immediate expert consultation often leads to delays in treatment for high-risk patients.
• Data Fragmentation: Difficulty in tracking the evolution of moles and skin changes over long periods using traditional manual records.

Solution

Folio3 developed a comprehensive, HIPAA-compliant digital ecosystem that brings Speclipse’s clinical-grade AI to a mobile-first environment. The solution integrates a cross-platform mobile app for patients with a specialized GP portal for clinicians.

• LIPS-AI Integration: We built a system that processes complex spectral data from Speclipse’s hardware, delivering real-time molecular-level diagnostic scores.
• Digital Dermatology Hub: A dual-phase architecture including an AI-driven screening app and a virtual teleclinic for instant dermatologist consultation.
• Full-Body Intelligence: An interactive, gender-based body map that utilizes AI to automate the tracking of skin lesions over time.

Key Features

• AI-Driven Image Diagnosis: Users capture close-up images of skin anomalies; the AI engine assesses them for cancer risk using deep neural network training.
• Automated Risk Scoring (SSS): Real-time generation of the Spectra-Scope Score (SSS) to quantify the probability of malignancy.
• Intelligent Skin Mapping: AI-enabled body mapping that stores a visual history of every mole, automatically highlighting "evolving" spots.
• Telehealth & GP Portal: Integrated secure chat and document sharing, allowing GPs to review AI-generated reports and images for remote triage.
• Real-Time Environment Tracking: AI-integrated UV index monitoring that provides personalized precautions based on the user's geolocation and skin profile.

Result

• High Diagnostic Accuracy: Achieved 95% sensitivity and 87% specificity in detecting various skin cancers, significantly reducing unnecessary biopsies.
• Accelerated Triage: Reduced the time from initial observation to expert consultation through integrated AI screening and telehealth.
• Global Scalability: Successfully deployed in over 20 countries with certifications in Australia, Europe, and Brazil.
• Improved Patient Engagement: Significant increase in proactive self-monitoring through AI-driven reminders and interactive body tracking.